Urolithin A — Research Profile

What the Research Says

The research landscape for Urolithin A is characterized by a transition from robust mechanistic evidence in cell cultures to emerging, though limited, human clinical data. While animal models and in vitro studies provide strong evidence for its role in stimulating mitophagy—the lysosomal degradation of damaged mitochondria—human-centric evidence is currently restricted to a small number of pilot RCTs. A notable 2022 study involving 30 participants demonstrated that daily supplementation with 1g of Urolithin A over 30 days may improve muscle function and reduce muscle damage markers, but the small sample size prevents broad generalization. Further large-scale, long-term human RCTs are required to confirm its efficacy for sarcopenia prevention and metabolic health.

Benefits of Urolithin A

• Mitophagy induction — Urolithin A stimulates the clearance of damaged mitochondria via the PINK1/Parkin-mediated mitophagy pathway, potentially improving mitochondrial quality control.
• Muscle function preservation — a small-scale RCT in older adults (n=20) demonstrated that 1000mg daily for 30 days improved muscle endurance and strength, specifically in tasks like the 6-minute walk test.
• Skeletal muscle endurance — preliminary human data suggests Urolithin A may enhance aerobic capacity and muscular endurance by optimizing mitochondrial oxidative capacity, though long-term effects in athletic populations require more large-scale RCTs.
• Cellular longevity markers — animal models (C. elegans and Drosophila) show significant increases in lifespan and healthspan, likely through the reduction of mitochondrial-derived reactive oxygen species (ROS).
• Metabolic health support — emerging evidence suggests Urolithin A may improve insulin sensitivity and glucose metabolism by enhancing mitochondrial efficiency, though most current human data is limited to small cohorts and short durations.

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

• Gastrointestinal distress, including nausea or abdominal discomfort, primarily reported in small-scale human trials during acute administration.
• Potential for hypoglycemia in diabetic populations; while human RCTs are limited, the metabolic modulation of mitophagy-related pathways necessitates caution regarding glucose homeostasis.
• Lack of long-term safety data; current human clinical evidence is restricted to short-duration studies (typically 4–12 weeks), leaving long-term effects on systemic mitophagy levels uncharacterized.
• Potential for unknown interactions with drugs targeting mitochondrial biogenesis or metabolic rate, due to the lack of comprehensive pharmacokinetic studies in humans.

Drug & Supplement Interactions

• Potential synergistic effects with mitophagy-inducing agents: Because Urolithin A functions via the activation of PINK1/Parkin-mediated mitophagy, concurrent use with other autophagy-modulating compounds (such as spermidine) lacks sufficient human RCT data to determine if additive effects occur or if cellular signaling pathways reach a saturation point.
• Pharmacokinetic considerations with CYP450 substrates: While human data is limited, Urolithin A is a metabolite produced by gut microbiota from ellagitannins; there is a theoretical risk that high-dose supplementation could influence the metabolic clearance of drugs processed via the cytochrome P450 system, though specific inhibitory or inductive potencies remain uncharacterized in clinical trials.
• Interaction with anti-inflammatory or immunosuppressant drugs: Given Urolithin A's role in modulating inflammatory signaling pathways (such as NF-κB inhibition), there is a theoretical risk of interference with the efficacy of pharmaceutical-grade immunosuppressants or corticosteroids, though no specific clinical studies have quantified this interaction.